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VITAMIN D IN CROHN’S DISEASE 
JEFFREY JOHN LEWANDOWSKI 
ABSTRACT 
Background 
During the mid to late 20th century, parts of Europe and North America began 
experiencing increasing incidence of inflammatory bowel disease for unknown reasons. 
Epidemiological studies carried out at the time determined that incidence rates and 
disease severity were higher in the northern latitudes than in the southern latitudes.  
Literature review 
In the ensuing years, an inverse association was established between ultraviolet radiation 
and incidence of Crohn’s disease, a finding that has not proven to be as robust for 
ulcerative colitis. This association was explored further and vitamin D was implicated to 
be the factor of ultraviolet radiation which was associated with increased incidence. 
Currently, all evidence implicating vitamin D in the pathogenesis of Crohn’s disease 
comes from epidemiological, animal, and in vitro studies, providing strong evidence for 
an association, but none of which can prove causality. Causality must be proven in 
prospective clinical trials, which, at present, have come up short in providing statistically 
significant findings.  
Methods 
The proposed trial outlined below provides a method of studying the question at hand in a 
way that has not been previously studied. This is a randomized, double blind, controlled 
		 vi 
trial which assesses the effect of supplementation of vitamin D in patients with active 
Crohn’s disease.  
Discussion 
Acceptance of the alternative hypothesis would be a big step forward in the management 
of Crohn’s disease. It would have wide-ranging implications, resulting in decreased 
healthcare costs, decreased use of toxic medications, and increased quality of life.  
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INTRODUCTION 
Background 
Dating back to the early 1970s, investigations began focusing on what might be the cause 
of the increasing incidence of inflammatory bowel disease (IBD) across Europe.1,2 
Epidemiological studies began showing that perhaps some environmental factor was 
influencing the pathogenesis of the disease.1–4 Over the course of the next few decades, 
epidemiological studies progressed from showing an association between IBD and urban 
environments1,5, to establishing a north-south gradient, with higher incidence and more 
severe disease being found in the north3,4,6–9, and, finally, linking this north-south 
gradient to differences in ultraviolet (UV) light exposure.10–14  
At the same time, research involving the molecular effects of vitamin D was 
emerging. Classically, understanding of the function of vitamin D was limited to calcium 
and phosphorus homeostasis. It wasn’t until the early 1980s that understanding of the role 
of vitamin D expanded to include immune function.15–18 In the early 2000s, it started 
becoming clear that vitamin D was the aspect of UV light that resulted in its association 
with IBD.19–23 This fit with prior research showing that IBD patients tend to be more 
vitamin D deficient than controls.24–26 Research was also emerging associating vitamin D 
with similar autoimmune diseases such as Multiple Sclerosis (MS).27  
 
Statement of the Problem 
Currently, most data point to an association between vitamin D and Crohn’s disease 
(CD), but a causal relationship has been difficult to establish. This association is less 
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clear for ulcerative colitis (UC).10,28,29 Most of the data supporting causality lie in basic 
laboratory research linking vitamin D with certain immunologic processes that are known 
to be related to CD pathogenesis. In order to establish causality, clinical trials must show 
that disease activity decreases with vitamin D supplementation. At this point, there have 
only been a couple of clinical trials performed, both which show a trend toward decrease 
in disease activity with vitamin D supplementation, but neither definitively doing so.21,30 
 Establishing a causal role of vitamin D in the pathogenesis of CD would be 
important for many reasons. While there have been a number of recent advances in the 
medications used to treat CD, the treatments that are currently available place a huge 
financial burden on society and, despite the high costs, many patients cannot be 
effectively controlled with them.31,32 In addition, these medications are associated with 
numerous side effects that have a big impact on quality of life (QOL) of patients living 
with CD.33 Providing evidence of a causal role in the pathogenesis of CD could lead 
vitamin D supplementation to become a valid therapeutic option in CD. This could have 
wide-ranging effects including reduced costs, a reduced number of toxic medications 
necessary to achieve remission, and an increased QOL.  
 
Hypothesis 
Vitamin D supplementation in patients with active Crohn’s disease will lead to higher 
rates of remission.  
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Objectives and specific aims 
Medications currently used to treat CD have many undesirable systemic toxicities. By 
supplementing active CD patients with high doses of relatively benign vitamin D, the 
goal is to prove that a causal relationship exists between vitamin D levels and disease 
activity, and that supplementation can lead to better outcomes.  
1. Using Crohn’s Disease Activity Index as a measure, assess whether patients with 
active CD benefit from supplementation with high doses of vitamin D. 
2. Assess the effect of vitamin D supplementation on objective measures such as 
biomarkers and vitamin D levels. 
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REVIEW OF THE LITERATURE 
Overview 
 
Crohn’s Disease 
IBD, which can be subdivided into CD and UC, is characterized by chronic relapsing and 
remitting inflammation of the gastrointestinal (GI) tract as a result of dysregulated 
mucosal immune activation. While CD and UC share many similarities, they are quite 
distinct in many ways (Figure 1). CD and UC are often distinguished by two important 
features. First, the lesions of CD may be isolated “skip lesions” and can occur anywhere 
along the GI tract, whereas UC is a continuous lesion beginning at the rectum and may 
extend proximally to involve the entire colon in more severe disease. Second, CD and UC 
are pathologically distinct. The lesions of CD tend to be transmural which contrasts with 
the lesions of UC which are limited to the mucosa and submucosa. Other distinguishing 
features of CD include presence of strictures, granulomas, fistulae, and fat/vitamin 
malabsorption.  
Incidence rates in North America range from 0 – 19.2 cases per 100,000 persons 
per year for UC and 0 – 20.2 cases per 100,000 persons per year for CD.34 Prevalence 
rates for the same region range from 37.5 – 248.6 cases per 100,000 persons per year for 
UC and 16.7 – 318.5 cases per 100,000 persons per year for CD.34 Worldwide, both 
incidence and prevalence rates appear to be rising.34 A new report issued by the Centers 
for Disease Control and Prevention showed that prevalence rates of IBD in the United 
States (US) may actually be nearly three times as high as originally thought, approaching 
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3.1 million, or 1.3% of US adults.35 Incidence rates for both UC and CD are highest in 
patients whose ages range from 20-29 years, Caucasians, and people of Jewish heritage.34 
Additional risk factors include family history of IBD, cigarette smoking, and 
appendectomy.36 
Figure 1. Differences in disease characteristics between Crohn’s disease and ulcerative colitis. (Adapted from 
Cheifetz, 2013)37 
 
The clinical manifestations of CD are extremely variable. Many patients complain 
of crampy abdominal pain, bloody or nonbloody diarrhea, fevers, weight loss, and 
fatigue. Due to the transmural nature of the inflammation, development of fistulae is 
fairly common, with a cumulative risk of 33% and 50% after 10 and 20 years, 
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respectively.38 Phlegmon and abscesses are two other complications of the inflammation 
of CD. Many patients suffer from perianal complications including large skin tags, anal 
fissures, perirectal abscesses, and anorectal fistulae. Extraintestinal manifestations 
include arthritis, eye involvement such as uveitis, episcleritis, and iritis, skin disorders 
such as erythema nodosum and pyoderma gangrenosum, primary sclerosing cholangitis, 
gallstones, and osteoporosis. 
Diagnosis of CD is made based on a combination of clinical, laboratory, 
endoscopic, radiologic, and histologic features. Laboratory tests may show anemia, iron 
deficiency, B12 deficiency, elevated white blood count, and elevated erythrocyte 
sedimentation rate or c-reactive protein. Fecal calprotectin is a stool marker of intestinal 
inflammation, not generally used in clinical practice, that has high sensitivity and 
specificity for IBD.39 Endoscopic features of CD include isolated “skip lesions,” 
occurring most commonly in the small bowel and colon, but may affect any portion of the 
GI tract. The lesion of CD generally starts as an aphthous ulcer, and multiple lesions may 
coalesce into an elongated, linear ulcer running along the long axis of the bowel. 
“Cobblestoning” is a common endoscopic finding, referring to the appearance of the 
mucosa when diseased tissue is depressed below the level of the adjacent normal mucosa. 
Radiologic imaging can be used when trying to assess parts of the GI tract not accessible 
by endoscopy. Imaging modalities include barium studies, computed tomography scan, or 
magnetic resonance enterography. Histologically, crypt abscesses, noncaseating 
granulomas, and transmural inflammation may be seen.  
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The disease typically takes on a relapsing and remitting course, resulting in a 
considerable reduction in quality of life.33 Overall, a continuous course of active disease 
occurs in 5%, a relapse-free course occurs in 13%, yearly relapses occur in 20%, and a 
combination of years in relapse and remission occurs in 67%.40 If a patient is in remission 
for one year, there is an 80% chance they will remain in remission over the course of the 
next year.40 If a patient has active disease in the past year, there is a 70% chance they will 
be active over the course of the next year and a 50% chance they will attain remission 
over the next three years.40  
Treatments for CD include antibiotics, aminosalicylates, corticosteroids, 
immunomodulators, and biologics, all of which can have significant side effects and 
deficiencies (Table 1). Due to the chronic lifelong nature of the disease, the chances of a 
patient being adversely affected by one of these medications at some point in their life is 
very real. Therefore, there is an inherent need to develop less toxic treatments which alter 
the course of the disease without potentially causing additional harm to the patient. 
One of the most recent advances in the treatment of CD is tumor necrosis factor 
alpha (TNF-a) inhibitor, a biologic which targets the adaptive immune system. Anti-
TNF-a has become a popular approach to treatment due to its relatively high rates of 
efficacy.40 Despite this, only about a third of patients achieve remission with this 
medication, and many of those who do are not able to maintain remission.32 Additionally, 
anti-TNFa is associated with a wide range of adverse effects.41 Other novel therapies, 
such as those which target a4-b7 integrins, have proven to be not superior in efficacy to 
anti-TNFa medications and carry their own potential toxicities.41–43 Another limitation is 
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the high cost of the current therapeutics.44 In a Dutch study which evaluated the main cost 
drivers of IBD, anti-TNFa therapy was identified as the major driver in cost, accounting 
for 64% of the total cost of CD, followed by hospitalization (19%), productivity losses 
(16%), and surgery (<1%).31 Due to the substantial morbidity associated with CD and 
limitations of the current therapies, new therapies or adjunctive therapies are essential.  
Table 1. Medications used for the treatment of Crohn’s disease. (Adapted from Cheifetz, 2013.)37 
Medications	 Induction	of	
Remission,	
%	of	
Patients	
Level	of		
Evidencea	
Maintenance	
of	Remission,	
%	of	Patients	
Level	of		
Evidencea	
Common	Adverse	
Effects	
Rare	Adverse	Effects	
Aminosalicylates	(sulfasalazine,	mesalamine)	 Limited	or	no	role	for	mesalamine;	sulfasalazine	may	be	considered	for	mild	Crohn	colitis	
III,	A	IIb,	B	 No	role	 III,	B	 Nausea,	vomiting;	headache;	reversible	male	infertility	(sulfasalazine)	
Interstitial	nephritis	
Corticosteroids	 70-80	 I,	A	 No	evidence	of	benefit	 III,	A	 Steroid	adverse	effects	 	Budesonide	 50-70	 I,	A	 No	evidence	of	benefit	beyond	6	mo	 III,	A	 Steroid	adverse	effects	 	Thiopurines	(azathioprine,	mercaptopurine)	 55	(Slower	onset	of	action)	 IIa,	B	 50-70	 I,	A	 Nausea,	vomiting;	pancreatitis;	infection;	bone	marrow	suppression;	liver	toxicity	
Lymphoma	
Methotrexate	(intramuscular)	 40	(Slower	onset	of	action)	 IIa,	B	 65	 I,	B	 Nausea,	vomiting;	infection;	liver	toxicity;	contraindicated	in	pregnancy	
Pulmonary	
Anti-TNFs	(infliximab,	adalimumab,	certolizumab)	
60-80	 I,	A	 40-60	 I,	A	 Infection;	infusion/injection	reactions	 Lymphoma;	heart	failure;	demylination	Natalizumab	 61	(indicated	in	anti-TNF	failures)	 IIa,	B	 44	 IIa,	A;	depends	on	JC	virus	antibody	status	
Infection	 Progressive	multifocal	leukoencephalopathy;	JC	virus	antibody	test	should	be	performed	prior	to	initiation	a	American	Heart	Association	levels	of	evidence:	I:	Benefit	>>>	risk.	Treatment	should	be	administered.	IIa:	Benefit	>>	risk,	but	additional	studies	with	focused	objectives	are	needed.	It	is	reasonable	to	administer	treatment.	IIb:	Benefit	≥	risk,	but	additional	studies	with	broad	objectives	are	needed;	additional	registry	data	would	be	helpful.	Treatment	may	be	considered.	III:	No	benefit	or	harm.	Procedure	not	helpful	or	harmful.	Treatment	has	no	proven	benefit	or	is	harmful.	A:	Multiple	populations	evaluated.	Data	derived	from	multiple	randomized	controlled	trials	or	meta-analysis.	B:	Limited	populations	evaluated.	Data	derived	from	a	single	randomized	controlled	trial	or	nonrandomized	studies.	C:	Very	limited	populations	evaluated.	Only	consensus	opinions	of	experts,	case	studies,	or	standard	of	care	
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Vitamin D 
 
Dating back to the 1600s, a disease characterized by growth retardation, deformities of 
the legs and ribcage, and muscle weakness plagued children inhabiting the highly 
polluted, industrialized cities of northern Europe.45 This disease would come to be known 
as rickets and was found to be preventable and treatable with adequate sunlight.45 In the 
late 19th and early 20th centuries, incidence of rickets peaked, occurring in an estimated 
96% of children younger than 18 months in one study.46 It was soon found that rickets 
could also be treated with dietary modifications, namely increasing the intake of milk, 
butter, and cod liver oil.46 It wasn’t until the early 1900s that the factor in sunlight which 
treated this disease was identified as vitamin D.45,46 
Vitamin D is a secosteroid which humans obtain primarily through sunlight, with 
the remainder coming from diet.47 In the skin, 7-dehydrocholesterol is converted to 
previtamin D3 and then to vitamin D3 upon exposure to UVB radiation. Vitamin D3 from 
the skin along with vitamin D2 and vitamin D3 from the diet, which are stored in fat cells 
and transported via vitamin D-binding protein to the liver, are converted to 25-
hydroxyvitamin D [25(OH)D] by the hepatic enzyme, vitamin D-25-hydroxylase. This 
form, 25(OH)D, is the form used to measure vitamin D levels in the clinical setting.48 The 
inactive 25(OH)D is then transported to the kidneys where the enzyme 25-
hydroxyvitamin D-1a-hydroxylase converts it to the active 1,25-dihydroxyvitamin D 
[1,25(OH)2D]. 1,25(OH)2D is then broken down to calcitroic acid, which is biologically 
inactive and excreted in the bile.  
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Vitamin D is essential for maintaining bone density, and does so through a 
number of mechanisms involving the GI tract, bone, and kidney. 1,25(OH)2D acts on the 
vitamin D receptor (VDR) in the small bowel epithelium to stimulate the production of an 
epithelial calcium channel as well as a calcium binding protein, resulting in an increase 
dietary calcium absorption from approximately 10-15% to 30-40%.47 Similarly, 
1,25(OH)2D brings intestinal phosphorus absorption from 60% of dietary phosphorus to 
about 80%.47 1,25(OH)2D has an additional effect on the distal renal tubule, resulting in 
additional calcium reabsorption.49 Plasma calcium levels are very strictly regulated in the 
human body, therefore, in the absence of adequate levels of vitamin D, and resultant fall 
in dietary absorption of calcium and phosphorus, calcium must be mobilized from its 
main store in the body – the bone. Parathyroid hormone, released from the parathyroid 
glands in the presence of low plasma calcium and vitamin D levels, acts in conjunction 
with vitamin D to stimulate differentiation of osteoclasts which resorb bone and liberate 
calcium.50 By maintaining vitamin D levels at the optimal range, the parathyroid glands 
are effectively turned off by a negative feedback mechanism, and bone resorption 
ceases.50  
It has been established, however, that the role of vitamin D moves far beyond the 
bone. The discovery of the VDR in a multitude of other tissues, including skin, colon, 
brain, pancreas, breast, and immune cells was the first indication that perhaps vitamin D 
had effects outside of calcium homeostasis.15,16,51–55 Coupled with the finding of 1a-
hydroxylase, the enzyme which converts inactive 25(OH)D to active 1,25(OH)2D, in a 
number of different cell types made it increasingly clear that vitamin D had far reaching 
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effects in the human body.56–59 Currently, the role of vitamin D has been expanded to 
include effects on muscle strength and falls, cancer, the immune system, cardiovascular 
disease, diabetes, schizophrenia, and lung function (Appendix A).47  
The optimal level of serum 25-hydroxyvitamin D is controversial.48 The Institute 
of Medicine (IOM) describes a range of 20-40 ng/mL (50-100 nmol/L) to be optimal, 
although many experts believe levels below 30 ng/mL (75 nmol/L) to be 
suboptimal.47,48,60 Using 20 ng/mL as the cutoff, it is estimated that the overall prevalence 
of vitamin D deficiency is 41.6%, a number that has been increasing worldwide.61,62 Risk 
factors for deficiency include non-white race, lack of college education, obesity, poor 
health status, hypertension, low high-density lipoprotein cholesterol, and lack of daily 
milk consumption.61 
 
Vitamin D and Crohn’s Disease 
 
During the mid 20th century, parts of Europe and North America began observing rapidly 
increasing incidence of IBD for unclear reasons.1,2,63 Epidemiological studies carried out 
at the time revealed one piece of evidence that was apparent – the increased risk of 
developing IBD when living in the city.1,2,5 This raised the question, what is it about the 
urban environment that predisposes its inhabitants to IBD? One obvious difference 
between the urban and rural environments at that time, and still today, is one of the major 
adverse effects of the industrial revolution – air pollution. In his article, Kyle (1971) 
refutes the idea that his findings would be the result of air pollution, as the area in which 
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his cohort lived, Aberdeen, Scotland, “…has only a few light industries and relatively 
clean air.”1 There must be, he argued, other environmental factors that give rise to IBD.  
 Many studies analyzing trends of IBD were conducted over the subsequent years. 
Sonnenberg (1991), using Medicare data of 1986 and 1987, showed conclusively for the 
first time that there was a north-south gradient of IBD severity.3 Although this study was 
not the first to notice this geographic distribution, it was the most convincing due to the  
breadth of land area it covered and number of participants.3 Various studies across 
Europe came to similar findings, but, like some of the early US studies, they were hard to 
interpret and analyze together due to differences in methodology.4 In 1988, a group of 
European gastroenterologists convened and developed a plan to study the trends of IBD 
emerging in Europe and North America. What followed was the European Collaborative 
Study on Inflammatory Bowel Disease (EC-IBD).4 The data that emerged showed a 
convincing north-south gradient which could not be explained by differences in certain 
confounders such as tobacco or education.4 It was now becoming increasingly clear that 
there were some unknown environmental factors involved in the pathogenesis of IBD. 
 Further studies emerged showing clear north-south gradients in incidence of CD 
in Scotland6 and France7,8. Interestingly, this gradient didn’t hold true for UC in most 
studies6–8, but not all.9 In investigating what differences exist between the north and south 
of France, Nerich (2006) proposed several possibilities including diet, sunlight, tobacco 
consumption, and genetic variation.7 Given emerging data that sunlight might be 
protective in MS27, and ultraviolet radiation plays a role in immune function64, research 
on what effect, if any, ultraviolet radiation plays in the pathogenesis of IBD naturally 
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followed. Not unexpectedly, results exhibited an inverse relationship between UV 
radiation and incidence of CD10 as well as disease severity of both CD and UC.12,14 In a 
French study analyzing the geographic distribution of IBD incidence in relation to UV 
exposure, it was found that there is a certain amount of UV radiation, above which is 
protective of CD and below which there is an increased incidence of CD.10 Similar 
findings were found in a prospective cohort of French women followed for more than 15 
years, known in France as E3N or “L'Étude Épidémiologique auprès de femmes de la 
Mutuelle Générale de l' Éducation Nationale.”11 With evidence pointing to a role of 
vitamin D in the immune system65 and having effects on related diseases such as MS27, 
the idea that perhaps vitamin D played a role in the pathogenesis of IBD emerged.  
While observational studies are very important in establishing association at the 
population level, they fall short in their ability to infer causal relationships. There are a 
number of factors that can be established which increase the likelihood of statistical 
association being causal. These include strength of the association, consistency, 
specificity, biologic plausibility, and dose-response relationship.66(pp50-58) While there are 
a number of observational studies for vitamin D and CD which show strength of 
association, consistency of the association, specificity, and a few show a dose-response 
relationship, observational studies cannot reliably establish biologic plausibility. This, 
however, has been established in numerous in vitro and animal models. 
 
Vitamin D and the immune system 
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Investigations into the effects of vitamin D on the immune system began in the early 
1980s, soon after it was discovered that children with rickets exhibited an impaired 
neutrophil function, resulting in frequent infections.67 In 1981, it was first demonstrated 
that neutrophils and macrophages from vitamin D deficient mice had decreased migration 
and phagocytic response, respectively, and that the phagocytic response was correctable 
by administration of vitamin D.54 During this same year, it was also established that 
vitamin D was involved in the differentiation of myeloid cells into macrophages, and the 
presence of a VDR in monocytes as well as active T and B lymphocytes was discovered 
soon after, expanding its role from primarily bone metabolism to immune function.15,16,55 
In conjunction with these findings, studies demonstrating the presence of 1a-hydroxylase 
in monocyte-derived macrophages and dendritic cells strengthened the argument for a 
role of vitamin D in the immune system (Table 2).57–59 
Table 2. The influence of 1,25(OH)2D3 in the regulation of mediators produced by immune cells. (Adapted from 
Maruotti and Cantatore, 2010)68 
Action of 1,25(OH)2D3 
on Immune Mediators 
Producing Cells 1,25(OH)2D3 Effects  Reference  
¯ IL-1 Dendritic cells, macrophages ¯ Flogosis  69  
¯ IL-2 TH1 cells ¯ T cells, ¯ Antigen presentation  70  
­ IL-4 TH2 cells ­ TH2 cells  
20,71  
­ IL-5 TH2 cells ­ B cell, ­ eosinophils  20,71  
¯ IL-6 T cells, macrophages ¯ TH17 cells  
72  
­ IL-10 Dendritic cells ­ Regulatory T cell activation  69,72  
¯ IL-12 Dendritic cells, macrophages ¯ TH1 cells  
72  
¯ IL-17 TH17 cells ¯ Immunological response  73  
¯ IL-23 Macrophages ¯ TH17 cells  
72  
¯ Immunoglobulins B cells ¯ Immunological response  74  
¯ TNF-a Macrophages ¯ Flogosis  69  
¯ IFN-g TH1 cells ¯ T cells, ¯ Antigen presentation  75  
¯ CD40 Antigen-presenting cells ¯ T cell activation  76  
¯ CD80 Antigen-presenting cells ¯ T cell activation  76  
¯ CD86 Antigen-presenting cells ¯ T cell activation  76  
­ FoxP3 Dendritic cells ¯ Regulatory T cell activation  72  
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T lymphocytes are an essential component of the immune system. Comprised of 
CD4+ and CD8+ cells, the major function of T lymphocytes is cell-mediated immunity – 
the destruction of cells with intracellular pathogens including viruses, certain bacteria, 
protozoa, and fungi. T lymphocytes also mediate defense against extracellular pathogens 
by promoting antibody production in B lymphocytes and recruitment of other immune 
cells to the site.  
T lymphocytes carry out these diverse functions by differentiating into at least 3 
different subsets of CD4+ cells known as T helper (TH) cells. The TH1 subset produces 
interferon-l (IFN-l), a cytokine which acts as a potent activator of macrophages and 
stimulates IgG production. Overall, TH1 cells, via IFN-l, promote the ingestion and 
destruction of microbes by phagocytes. TH2 cells produce interleukin (IL) -4, IL-5, IL-10, 
and IL-13. These cytokines stimulate immunoglobulin (Ig) E production, mast cell 
activation, and eosinophil activation, with the ultimate outcome being defense against 
helminthic parasites. Additionally, these cytokines activate macrophages in the 
alternative pathway – enhancing functions such as tissue repair and counterbalancing the 
microbicidal effect of TH1 cells. TH17 cells produce IL-17 and IL-22, with the ultimate 
effect of inducing neutrophilic and monocytic inflammation at a site of antigen 
recognition – an essential defense against extracellular pathogens. 
In T lymphocytes, the overall effect of vitamin D is to polarize the cells toward a 
TH2 phenotype, promoting tolerance. Vitamin D downregulates IL-2 synthesis, inhibiting 
proliferation of all subtypes of T lymphocytes.71,77 Vitamin D has also been shown to 
increase IL-10 synthesis resulting in suppression in inflammatory cytokine secretion and 
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antigen presenting capacity of macrophages.78 In TH1 cells, vitamin D downregulates 
IFN-l and IL-12 synthesis, effectively suppressing the cell-mediated immunity actions of 
these cells.72 Vitamin D promotes the effects of TH2 cells by upregulating IL-4 and IL-5 
synthesis.20,71 Additionally, vitamin D inhibits the pro-inflammatory effects of TH17 cells 
by downregulating IL-17 synthesis.72 
The effect of vitamin D on B lymphocytes has also been studied, as patients with 
Systemic Lupus Erythematosus tend to be more vitamin D deficient than healthy 
controls.74 Vitamin D has been shown to have a direct effect on B lymphocytes, 
inhibiting proliferation and inducing apoptosis.74 In addition, these cells contain mRNA 
for vitamin D related proteins such as 1a-hydroxylase, 24-hydroxylase, and VDR.74 
Cells of the mononuclear phagocyte system contain 1a-hydroxylase, 24-
hydroxylase, and VDR as well.58 Vitamin D plays a key role in the maturation of 
monocytes to macrophages and has direct immunomodulating properties by 
downregulating toll-like receptor (TLR) 2 and TLR4 in a time and dose-dependent 
fashion, representing an important anti-inflammatory effect.79,80 TLRs are expressed on 
the surface of cells of the innate immune system and their function is to identify and 
respond to microbial components such as bacterial lipoglycans or lipopolysaccharides. 
The downregulation of TLR in these cells results in decreased signaling downstream and 
a decrease in the production of many pro-inflammatory cytokines, including TNF-a. 
Vitamin D also has an effect on dendritic cells, inhibiting their differentiation and 
maturation and modulating their activation and survival, ultimately leading to T cell 
hyporesponsiveness and activation of regulatory T cells.72,81 
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There are a number of different animal models used in the study of IBD.82 IL-2 
knockout (KO) and IL-10 KO mice produce symptoms similar to IBD by creating a pro-
inflammatory state in which regulatory T cells are not properly functioning and tolerance 
to the normal gut flora is lost.82 Other models include induction of chemical injury 
directly to the intestines of mice using chemicals such as dextran sodium sulfate (DSS), 
which causes mucosal epithelial damage and subjects the submucosa to numerous 
antigens of the gut’s normal microbial flora.82 These models, in addition to many others, 
serve as important research tools which help in the identification of the pathogenesis of 
IBD and potential treatments for the disease. When studied in conjunction with vitamin D 
deficiency, the models have clarified many questions about the role of vitamin D in IBD. 
IL-10 is a regulatory cytokine produced by a number of different immune cells 
which functions to suppress the immune response by inhibiting macrophages and TH1 
cells. IL-10 KO mice develop enterocolitis within 5-8 weeks of life and the mortality rate 
of these mutants is about 30% at 3 months.83 The enterocolitis is presumably due to a 
breakdown of tolerance to the normal gut flora and an enhanced TH1 response since mice 
raised in pathogen-free facilities have milder disease.83 When combined with VDR KO, 
mortality rises to 100%.20 Additionally, treatment with 1,25(OH)2D results in suppression 
of these symptoms.19 
When the immune organs of IL-10 VDR double knockout (DKO) mice are 
examined, findings include thymic atrophy, splenomegaly containing more erythrocytes 
and less lymphoid cells, and mesenteric lymph node enlargement with more lymphoid 
cells when compared to IL-10 KO mice.84 When T cells are examined, they are found to 
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be of memory phenotype and hyporesponsive.84 Cytokines display high expression of 
pro-inflammatory cytokines such as IL-2, IFN-g, IL-1b, TNF-a, and IL-12.84 Taken 
together, these findings indicate that vitamin D has important anti-inflammatory 
mechanisms in the adaptive immune system. 
Severe combined immunodeficiency (SCID) mice, lacking B cells and T cells, are 
useful in the study of the immune system due to the ability to isolate a certain cell or 
subset of cells and to study its function. The CD45RB transfer model involves the use of 
SCID mice who are given normal B cells and a subset of CD4+ T cells which express 
high levels of the surface molecule CD45RB.82 CD45RB is a tyrosine phosphatase which 
regulates the activation of T and B cells. The mechanism by which these mice develop 
colitis is believed to be through a TH1 cell response mediated by IFN-l, TNF-a, and IL-
2.20,82 When combined with VDR KO, VDR KO CD4+ CD45RBhigh T cells transfer a 
more severe form of colitis to Rag KO (leukopenic) mice than CD45RBhigh T cells alone, 
again implicating vitamin D in regulation of the adaptive immune system.20 
In contrast to the IL-10 and CD45RBhigh models, DSS induced colitis occurs due 
to stimulation of the innate immune system followed by the adaptive immune system, 
evidenced by the fact that SCID mice, which have intact innate immunity but lack 
adaptive immunity, still develop acute colitis when treated with DSS.82 When DSS is 
administered to VDR KO mice, these mice develop more severe colitis than wild type 
(WT) mice.85 Upon closer examination of these mice, it becomes clear that cause of this 
severe form of colitis is multifactorial. First, VDR KO mice have dysregulated control of 
the intestinal epithelium, leading to a gut that is more vulnerable to damage by DSS.85 
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This confirms the findings of prior studies which show evidence of VDR and 
1,25(OH)2D3 control of cell growth and differentiation in intestinal epithelial cells.51,86 
Second, the VDR KO mice display significantly increased proinflammatory cytokines 
and chemokines compared at either 5 days or 10 days post DSS treatment.85 Among the 
factors found to be significantly higher include the cytokines TNF-a, IL-12p70, IFN-l, 
IL-1a, IL-1b, and IL-10, as well as chemokines normally involved in leukocyte 
recruitment macrophage inflammatory protein 1a (MIP-1a), and KC (CXCL1).85 Finally, 
it was observed that upon treatment with 1,25-(OH)2D3, DSS treated WT mice had 
increased IL-10 production and reduced symptoms of colitis.85 Overall, it appears based 
on these results that 1,25(OH)2D3 plays a key role in regulation of intestinal epithelial 
regeneration as well as of the innate immune system.  
 
Existing research 
Numerous lines of evidence point to there being multiple environmental factors that 
influence the pathogenesis of CD. Over 160 genetic loci associated with CD and UC have 
been identified, but even in light of this, these known genetic factors account for only a 
fraction of the risk of developing IBD.87–89 Additionally, certain epidemiologic 
observations, such as the drastically increasing incidence, particularly in Westernized 
nations and more recently in developing nations, provide strong evidence for the 
implication of environmental factors in the disease.34,90,91 These points, taken with the 
fact that the concordance rate for monozygotic twins is only 50% in CD and 18.8% in 
UC, the role of environmental factors in these diseases cannot be ignored.92  
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Vitamin D deficiency is a common problem among CD patients. In a meta-
analysis of 34 studies assessing the prevalence of vitamin D deficiency in CD, the overall 
prevalence was 57.7% [95% confidence interval (CI), 50.2-64.9%].93 This contrasts with 
an overall prevalence of 41.6% (95% CI, 36.6-46.8%) among US adults.61 
In order to assess the influence of vitamin D deficiency on disease incidence, two 
different methods have been employed. First, researchers have looked directly at 
25(OH)D levels to determine whether being deficient is a risk factor for disease. The 
problem with this approach is that it is unclear whether low vitamin D levels are a cause 
or an effect of IBD. In other words, is being deficient in vitamin D actually a risk factor 
for disease, or is it the result of intestinal inflammation and consequent malabsorption of 
dietary vitamin D? The other way to assess the association between vitamin D levels and 
disease incidence is to attempt to quantify the amount of vitamin D’s main source, 
sunlight. It has been shown that UV exposure is the main determinant of vitamin D 
status, better than dietary intake or oral supplementation.47,94,95 By using methods such as 
meteorological satellites to measure UV radiation intensity, researchers have been able to 
estimate a person’s vitamin D status without directly measuring the levels. 
Many studies have shown that CD patients tend to be more deficient in vitamin D 
than controls (Figure 2). In a meta-analysis of 27 studies published through March 2015, 
Sadeghian et al. (2016) compared mean serum 25(OH)D levels between CD patients and 
healthy controls. Results of the meta-analysis showed mean serum 25(OH)D levels to be 
3.99 ng/mL (95% CI, 2.08-5.91) lower among CD patients.93 These results must be 
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interpreted with caution, however, since there was significant heterogeneity among the 
studies (I2 = 86.9%; P < 0.001).93  
Figure 2. Mean difference of serum 25(OH)D levels among patients with Crohn’s disease compared with healthy 
controls. (Adapted from Sadeghian et al. 2016)93 
 
While most of the studies assessing vitamin D status in CD patients are cross-
sectional or retrospective studies, Anathakrishnan et al. (2012), using data from the 
Nurses’ Health Study (NHS), took a different approach.96 The NHS is a prospective 
cohort which began in 1976 and is comprised of 121,700 registered nurses in the US, 
with follow-up questionnaires sent out on a biennial basis.96  The study used validated 
diet and physical activity questionnaires sent out in 1980 and 1986 to determine 
25(OH)D status, then looked at the data through 2008 to identify incidence of CD or UC 
in this cohort.96 In a comparison of patients in the highest quartile of predicted 25(OH)D 
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levels with those of the lowest quartile, the multivariate-adjusted hazard ratio (HR) was 
0.54 (95% CI, 0.30-0.99) for CD (Ptrend = 0.02).96 In another comparison of patients 
sufficient in vitamin D (predicted 25(OH)D > 30 ng/mL) and patients deficient in vitamin 
D (predicted 25(OH)D < 20 ng/mL), the multivariate-adjusted HR was 0.38 (95% CI, 
0.15-0.97) for CD (P = 0.048).96 Both of these multivariate analyses adjusted for age, 
smoking, oral contraceptive use, post-menopausal hormone therapy use, physical activity, 
and body mass index.96 With these results, Ananthakrishnan et al (2012). was able to 
show, for the first time, that these patients were deficient in plasma 25(OH)D prior to 
their diagnosis of CD.96 This was an important finding, as it provided data pointing 
toward a possible causal role in the pathogenesis of CD.  
Two studies were performed in France which evaluated incidence of CD relative 
to UV exposure. The first, published in 2011, used the National Health Insurance 
database in France to establish incidence of CD, then, using Meteosat, the European 
meteorological satellite to measure UV radiation intensity, explored the relationship of 
CD incidence and UV radiation in each of the 94 départements of France.10 Among 
regions with highest UV exposure (1.729-1.928 kJ/m2 per day), the incidence rate ratio 
(IRR) was 0.85 (95% CI, 0.74-0.98).10 Regions with intermediate sun exposure (1.488-
1.585 kJ/m2 per day) had IRR of 0.90 (95% CI, 0.78-1.04).10 The two regions with the 
lowest sun exposure (1.397-1.484 and 1.272-1.396 kJ/m2 per day) had IRR of 1.12 (95% 
CI, 1.00-1.26) and 1.42 (95% CI, 1.27-1.58), respectively.10 Hence, according to the data, 
there appears to be a threshold of sunlight where CD incidence increases. There is, 
however, one key limitation to this study. Use of the National Health Insurance database 
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didn’t allow the authors to control for other lifestyle factors such as tobacco, physical 
exercise, or vitamin D intake.  
This limitation was addressed in another French study published in 2014, using a 
different cohort, the E3N, or “L'Étude Épidémiologique auprès de femmes de la Mutuelle 
Générale de l' Éducation Nationale.”11 This was a prospective cohort of 98,995 French 
women who completed questionnaires on a biennial basis from 1990 – 2005. Among the 
data collected included dietary data, physical activity, skin complexion, tobacco use, 
BMI, post-menopausal hormone therapy, and level of education.11 When these variables 
were adjusted for, the risk of incident CD was significantly lower in regions with highest 
sun exposure (³1.75 kJ/m2 per day) compared with those with lowest sun exposure 
(<1.51 kJ/m2 per day), HR 0.49 (95% CI, 0.23-1.01) Ptrend = 0.04.11 This association was 
strengthened when exploring the relation between CD, UVR, and vitamin D intake, HR 
0.29 (95% CI, 0.11-0.80) Ptrend = 0.01.11 
 Early studies of CD and vitamin D showed an association between vitamin D 
deficiency and disease activity. In 1985, Harries et al. reported that patients with active 
disease, defined as Harvey-Bradshaw Index ³ 5, had concentrations of plasma 25(OH)D 
that were significantly lower than those with inactive disease.97 The authors hypothesized 
that this was due to a protein losing enteropathy, similar to what is seen with nephrotic 
syndrome.97 Tajika et al. (2004) found similar results in a Japanese cohort, concluding 
that patients with active disease and long-standing disease tend to be significantly more 
deficient in vitamin D than those with milder disease.98 Joseph et al. (2009) came to 
similar conclusions as the two previous authors in a cohort of Indian subjects.99 
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Interestingly, prior to 2011, studies assessing disease activity and vitamin D levels 
were, for the most part, attempting to identify the patients who were at increased risk of 
malnutrition or metabolic bone disease.97–99 Even with a wealth of epidemiological, in 
vitro, and animal evidence pointing to a causal role of vitamin D in IBD, vitamin D was 
regarded in these studies only as a result of severe disease, not as a potential cause.  
More recent studies have recognized the potential causal role of vitamin D in 
disease activity. In 2011, Ulitsky et al. attempted to bring the research closer to a causal 
role for vitamin D by questioning whether vitamin D deficiency was linked to increased 
disease activity and reduced health-related quality of life (HRQOL).28 Results of the 
study showed that vitamin D deficiency was associated with increased disease activity 
[regression coefficient 1.07 (95% CI, 0.43-1.71)] and diminished HRQOL [regression 
coefficient -2.21 (95% CI, -4.10 to -0.33)] in CD.28 However, the research method 
employed, a retrospective observational study, was only able to identify an association 
and could not imply causation.  
In a prospective analysis, Ananthakrishnan et al. (2013) evaluated a cohort of IBD 
patients with baseline 25(OH)D levels.100 Primary outcomes in this study included IBD-
related surgery or hospitalization.100 Patients who had multiple levels drawn were 
identified to determine the impact of normalization of 25(OH)D on these outcomes.100 
The authors found that 10% of patients with normal vitamin D levels (>30 ng/mL) 
underwent surgery, 13% of patients with insufficient vitamin D levels (20-29.9 ng/mL) 
underwent surgery [odds ratio (OR) 1.70 (95% CI, 1.24-2.34)], and 17% of patients with 
deficient vitamin D levels (< 20 ng/mL) underwent surgery [OR 2.05 (95% CI, 1.53-
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2.75)].100 Additionally, patients who normalized their vitamin D levels saw decreased risk 
of surgery [OR 0.56 (95% CI, 0.32-0.98)].100 The results of this study have a number of 
implications. First, the design of the study, being a prospective observational study, 
places vitamin D deficiency prior to the increase in disease severity. This is an important 
advance in the literature as it contrasts with previous retrospective studies which could 
not temporally separate the effect of vitamin D levels and disease severity. Second, the 
use of objective endpoints such as IBD-related surgery and hospitalization eliminated the 
potential for bias when using subjective endpoints such as disease activity scores. Third, 
the result of normalization of 25(OH)D levels on risk of surgery indicates that vitamin D 
might be biologically relevant to the pathophysiology of the disease, not just a marker of 
disease severity. 
Although there are many convincing studies23,28,100–103 which show an inverse 
correlation between plasma 25(OH)D levels and disease severity, this is not the case for 
all studies. One study, which classified disease severity using Pediatric Crohn’s Disease 
Activity Index (PCDAI), found no significant difference between groups who were 
vitamin D deficient or sufficient.104 Another study, which also used PCDAI, did not find 
a correlation between disease activity and vitamin D levels.105  
Observational studies can show an association between vitamin D and CD, and 
when coupled with convincing data providing biologic plausibility from animal and in 
vitro studies, as outlined above, these associations become much stronger. Causality, 
however, can only be proven in randomized controlled trials. 
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There have been only a couple of intervention studies that have explored the 
causal relationship between vitamin D deficiency and IBD. Jorgensen et al. (2010) 
designed a randomized control trial which included 108 patients with CD in remission to 
1200 International Units (IU) vitamin D3 or placebo, the primary endpoint being 
relapse.21 Results showed a trend toward significance, with lower relapse rates among 
vitamin D3 treated patients (13% relapsed) when compared to placebo (29% relapsed), 
but this finding was not significant (p = 0.06).21 The authors concluded that the study 
could have been underpowered, and perhaps significance would have been established 
with a larger sample size.21 
A small pilot study was carried out to establish the dose of vitamin D necessary to 
increase serum vitamin D levels to 40 ng/mL.30 Secondary outcomes included disease 
activity using Crohn’s Disease Activity Index (CDAI) score as well as the Inflammatory 
Bowel Disease Questionnaire (IBDQ), used to measure disease-specific quality of life.30 
The study demonstrated that vitamin D oral supplementation significantly reduced the 
unadjusted mean CDAI scores from 230 ± 74 to 118 ± 66 points after 24 weeks (p < 
0.0001).30 IBDQ scores increased from 156 ± 24 to 180 ± 26 after 24 weeks, representing 
better quality of life (p = 0.0004).30 
Given the wealth of data from observational, in vitro, and animal studies 
supporting a strong association between vitamin D deficiency and CD, there is a need for 
additional clinical trials which show that supplementation of vitamin D leads to better 
disease outcomes. Vitamin D has not only shown promise in ameliorating activity of CD, 
but also potentially decreasing risk of osteoporosis106 as well as colon cancer107 in this 
	27 
group of patients. With the cost of healthcare in the United States the highest that it has 
ever been,108 combined with the increasing incidence of CD worldwide,34,35 the need for 
an affordable, safe, and effective treatment for CD has never been greater.  
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METHODS 
Study design 
This will be a randomized, double blind, controlled trial examining the use of vitamin D 
supplementation on disease activity in a cohort of CD patients presenting as outpatients 
to the Boston Medical Center IBD center with a flare of their disease. 
 
Study population and sampling 
The study population will be recruited from the Dempsey Center for Digestive Disorders 
at Boston Medical Center. The center provides care for 800 IBD patients per year (1500 
visits per year), of which 25% have active disease. Patients must be 18 years of age or 
older and able to provide informed consent. Patients must have a clinical diagnosis of CD 
confirmed by standard techniques. To be eligible for the study, patients must also have 
active CD, defined as having a CDAI ³ 150. Patients who are pregnant, have 25(OH)D > 
80 ng/ml, or a previous diagnosis of irritable bowel syndrome will be excluded from the 
study.  
 All patients will be treated by their gastroenterologist based on the clinical 
situation. 
It has been reported that 70% of patients who have had active disease in the past 
year will remain active in the forthcoming year.109 This study will be powered at 80% and 
alpha at 5%. In order to detect a 15% decrease in the number of patients with active 
disease, and thus an absolute risk of remaining active of 55%, a sample size of 172 must 
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be used in each treatment arm. To account for a 10% dropout rate, we will recruit 190 
patients in each arm for a total of 380 patients. 
 
Intervention 
Patients meeting the inclusion criteria and providing informed consent will be 
randomized to one of two groups. Both groups will be given a 3-month supply of tablets 
organized by day in a pill card. All pills will look identical to the user. Group A, the 
treatment group, will receive a packet of tablets that contains 6 placebo tablets and 1 - 
50,000IU vitamin D tablet per week. Group B, the control group, will receive the 
standard-of-care 1000IU vitamin D supplement that will be taken daily. A box will be 
delivered to the site containing 10 group A pill cards and 10 group B pill cards, all of 
which are identical. These will be delivered to the study site on a rolling basis as patients 
are enrolled in the trial. Patients will be scheduled for follow-up appointments at 6 weeks 
and 12 weeks to assess the outcomes and receive their next 3-month supply of pills. At 
these appointments, patients will be asked to bring their pill cards back to assess 
compliance. 
 
Study variables and measures 
We will be measuring differences in induction and maintenance of remission between the 
two groups. Primary outcome will be remission defined as a CDAI < 150. Secondary 
outcome will be a decrease in CDAI of more than 70 compared with baseline during the 
12-week observation period. 
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Recruitment 
Patients will be recruited when they present for their appointment at the Dempsey Center 
for Digestive Disorders at Boston Medical Center. One week prior to their appointment, 
all patients meeting preliminary inclusion criteria (age ³ 18, active disease) will receive 
notification in the mail informing them of the basics of the study. These patients will be 
screened at their appointment and given further details about the study from the clinician 
and asked to sign an informed consent form. 
 
Data collection 
Each patient will be assigned a folder corresponding to their study number that will be 
stored in a locked folder in my office and retained for at least 2 years after study 
completion. The folder will contain the case report form for each office visit which will 
include CDAI variables, lab values (including 25(OH)D, CRP, hematocrit, calcium, and 
albumin), adverse events, and concomitant drug treatments. All components from the 
case report form will be stored in a password protected Microsoft Access database as well 
as an online database.  
 For 7 days prior to study enrollment, patients will be asked to complete the 
Patient Diary Card for Crohn’s Disease Activity Index. Patients subsequently enrolled in 
the study will be given a card at each clinic visit. A telephone call will be made to the 
patient 1 week prior to each subsequent clinic visit reminding them of their appointment 
and requesting that they fill out the Patient Diary Card.  
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Data analysis 
In analyzing the data, chi-square test of independence will be used. The 3x2 table that 
will be used in the analysis is shown in table 3. This data will be graphed using the 
Kaplan-Meier method which will analyze time to the primary endpoint of remission, 
defined as CDAI < 150 and a decrease in CDAI of more than 70, as a function of time. 
Cox proportional hazards regression will be used to measure for temporal significance. 
Table 3. 3x2 response table. 
 Remission Partial response No remission 
Group A (treatment) ____% ____% ____% 
Group B (control) ____% ____% ____% 
 
Timeline and resources 
The time frame for this study will be 32 months (Table 4). 
Table 4. Timeline for study. 
2/2017 – 4/2017 • BUMC IRB submission & approval 
4/2017 • Educate staff at Dempsey Center for Digestive Disorders 
4/2017 • Begin enrollment 
4/2019 • Enroll last patient 
4/2019 – 10/2019 • Analyze data 
• Prepare manuscript 
• Submit manuscript for peer-review 
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Resources 
• Personnel 
o Principle investigator 
o Co-investigators 
o 1 student to send letters to patients, remind patients to fill out Patient 
Diary Card 7 days prior to their appointment, extract laboratory data and 
fill out case report form 
• Special resources 
o Collaboration with investigational pharmacy service to create and store 
identically appearing 1,000 IU Vitamin D pills, 50,000 IU Vitamin D pills, 
and placebo pills 
o Storage space for case report forms 
o SPSS software for statistical analysis 
o  
Institutional Review Board 
Before initiating any part of this study, approval by the Boston University Medical Center 
Institutional Review Board (BUMC IRB) must be obtained. Since this protocol requires 
administration of a medication that is considered higher than the Institute of Medicine’s 
Dietary Reference Intake,60 this protocol will be submitted for full board review. Included 
with the application will be the informed consent form, recruitment materials, Patient 
Diary Card for Crohn’s Disease Activity Index, grant application, drug label information, 
and Data and Safety Monitoring Board charter.  
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CONCLUSION 
Discussion 
One potential advantage this trial design has over previous trials is in the use of patients 
with active disease. Jorgensen, et al. (2010) conducted a trial using patients with 
quiescent disease and tracked rate of relapse.21 Using patients with active disease could 
potentially result in higher compliance with the study drug, as these patients could be 
more motivated to achieve remission.  
Another potential advantage this trial has over previous trials is the prospective 
use of the CDAI Patient Diary Card. In this trial, each patient will be receiving a 
reminder phone call to fill this out over the 7 days prior to their appointment. This was 
the original intention when this index was developed and validated, but it has been 
suggested that this is commonly overlooked and patients are assisted by the examiner in 
retrospectively filling out this card.110 This approach introduces bias into the score and 
invalidates the findings. 
There are a couple of limitations to this study. First, current standard-of-care is to 
replete patients who are found to be vitamin D deficient. This will likely have an impact 
on the results in the sense that the effect size between the two groups will be smaller. 
This could either result in a b-error or a true-positive finding in which the effect is 
actually larger than reported. Second, a large portion of the CDAI total score is subjective 
and based on a patient’s own perception of his or her illness. This can vary from patient 
to patient and even in the same patient from one visit to the next. In fact, when this 
intrapatient variation was measured by the authors who developed the index, a pooled 
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standard deviation of replication of the CDAI score was 46 points.111 However, CDAI is 
considered the gold standard for evaluation of disease activity and has led to regulatory 
approval of several drugs. Additionally, it is common practice among gastroenterologists 
to use a patient’s subjective measures to guide treatment, so the results will likely be 
more clinically relevant and generalizable than if solely objective measures were used.  
 
Summary 
In summary, CD is a chronic debilitating disease which results in significantly decreased 
QOL and a high economic burden on society. This economic burden is only set to rise, as 
healthcare costs increase and incidence of the disease rises. The high cost of care for CD 
patients stems primarily from use of biologics, which have become a popular treatment, 
but even so have variable efficacy and many unwanted side effects.  
 Vitamin D has shown high potential to be a viable adjunctive treatment for CD, 
with promising evidence coming from numerous population, in vitro, and animal studies. 
Unfortunately, the current evidence points only to an association between vitamin D 
deficiency and CD incidence and activity. Prospective clinical trials, which would prove 
causality, have come up short, possibly due to methodological flaws.  
 Here, I have designed a prospective clinical trial which would bring the field 
much closer to answering the question of causality. If my hypothesis proves correct, the 
implications would be far-reaching – it could change the way CD patients are treated, 
decreasing the use of highly toxic agents, increasing QOL for countless people across the 
world, and decreasing healthcare costs. 
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Clinical and/or public health significance 
Currently, agents used in treatment of CD include antibiotics, aminosalicylates, 
corticosteroids, immunomodulators, and biologics. Along with each of these agents come 
a variety of undesirable side effects, and efficacy is such that many patients cannot be 
adequately managed with these.  
 In addition to the undesirable effects on the patient level, some of the most 
effective medications used in treatment of CD are also the most expensive. Biologics 
constitute the major drivers in cost for these patients.31 With the cost of healthcare the 
highest it has been in human history, there is an inherent need to develop medications that 
are more affordable, effective, and safer for the patient. 
 The discovery that vitamin D changes the course of disease could have wide 
ranging consequences, both at the level of the individual and population. While it is 
unlikely that vitamin D supplementation would be the sole treatment of CD in many 
patients, it is conceivable that it could decrease the amount of toxic medications required 
to attain remission, resulting in better QOL and lower cost. 
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APPENDIX A 
Synthesis and Metabolism of Vitamin D. (Adapted from Holick, 2016).95 
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“Schematic representation of the synthesis and metabolism of vitamin D for skeletal and non-skeletal function. 
During exposure to sunlight, 7-dehydrocholesterol in the skin is converted to previtamin D3. Previtamin D3 
immediately converts by a heat-dependent process to vitamin D3. Excessive exposure to sunlight degrades 
previtamin D3 and vitamin D3 into inactive photoproducts. Vitamin D2 and vitamin D3 from dietary sources 
are incorporated into chylomicrons, transported by the lymphatic system into the venous circulation. Vitamin D 
(D represents D2 or D3) made in the skin or ingested in the diet can be stored in and then released from fat cells. 
Vitamin D in the circulation is bound to the vitamin D-binding protein (DBP), which transports it to the liver, 
where vitamin D is converted by the vitamin D-25-hydroxylase to 25-hydroxyvitamin D [25(OH)D]. This is the 
major circulating form of vitamin D that is used by clinicians to measure vitamin D status (although most 
reference laboratories report the normal range to be 20-100 ng/ml, the preferred healthful range is 30-60 ng/ml). 
It is biologically inactive and must be converted in the kidneys by the 25-hydroxyvitamin D-1a-hydroxylase (1-
OHase) to its biologically active form 1,25-dihydroxyvitamin D [1,25(OH)2D]. 1,25(OH)2D3 is then taken up by 
target cells and targeted to intracellular D-binding proteins (IDBP) to mitochondrial 24-hydroxylase or to the 
vitamin D receptor (VDR). The 1,25(OH)2D3-VDR complex heterodimerizes with the retinoic acid receptor 
(RXR) and binds to specific sequences in the promoter regions of the target gene. The DNA bound heterodimer 
attracts components of the RNA polymerase II complex and nuclear transcription regulators. Serum 
phosphorus, calcium fibroblast growth factors (FGF-23), and other factors can either increase or decrease the 
renal production of 1,25(OH)2D. 1,25(OH)2D feedback regulates its own synthesis and decreases the synthesis 
and secretion of parathyroid hormone (PTH) in the parathyroid glands. 1,25(OH)2D increases the expression of 
the 25-hydroxyvitamin D-24-hydroxylase (24-OHase) to catabolize 1,25(OH)2D to the water-soluble, biologically 
inactive calcitroic acid, which is excreted in the bile. 1,25(OH)2D enhances intestinal calcium absorption in the 
small intestine by stimulating the expression of the epithelial calcium channel (ECaC) and the calbindin 9K 
(calcium-binding protein, CaBP). 1,25(OH)2D is recognized by its receptor in osteoblasts, causing an increase in 
the expression of the receptor activator of the NF-kB ligand (RANKL). Its receptor RANK on the preosteoclast 
binds RANKL, which induces the preosteoclast to become a mature osteoclast. The mature osteoclast removes 
calcium and phosphorus from the bone to maintain blood calcium and phosphorus levels. Adequate calcium and 
phosphorus levels promote the mineralization of the skeleton. Autocrine metabolism of 25(OH)D; when a 
macrophage or monocyte is stimulated through its toll-like receptor 2/1 (TLR2/1) by an infectious agent such as 
Mycobacterium tuberculosis or its lipopolysaccharide, the signal up-regulates the expression of VDR and 1-
OHase. A 25(OH)D level of 30 ng/ml or higher provides adequate substrate for 1-OHase to convert 25(OH)D to 
1,25(OH)2D in mitochondria. 1,25(OH)2D travels to the nucleus, where it increases the expression of 
cathelicidin, a peptide capable of promoting innate immunity and inducing the destruction of infectious agents 
such as M. tuberculosis. It is also likely that the 1,25(OH)2D produced in monocytes or macrophages is released 
to act locally on activated T lymphocytes, which regulate cytokine synthesis, and activated B lymphocytes, which 
regulate immunoglobulin synthesis. When the 25(OH)D level is approximately 30 ng/ml, the risk of many 
common cancers is reduced. It is believed that the local production of 1,25(OH)2D in the breast, colon, prostate, 
and other tissues regulates a variety of genes that control proliferation, including p21 and p27, as well as genes 
that inhibit angiogenesis and induce differentiation and apoptosis. Once 1,25(OH)2D completes the task of 
maintaining normal cellular proliferation and differentiation, it induces expression of the enzyme 24-OHase, 
which enhances the catabolism of 1,25(OH)2D to the biologically inert calcitroic acid. Thus, locally produced 
(autocrine) 1,25(OH)2D does not enter the circulation and has no influence on calcium metabolism. The 
parathyroid glands have 1-OHase activity, and the local production of 1,25(OH)2D inhibits the expression and 
synthesis of parathyroid hormone. The 1,25(OH)2D produced in the kidney enters the circulation and can down-
regulate rennin production in the kidney and stimulate insulin secretion in the beta islet cells of the pancreas. 
(With permission Holick copyright 2013).”95 	  
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APPENDIX B 
 
Patient Diary Card for Crohn’s Disease Activity Index. (Adapted from Best, 1976).111 
 
Patient	Diary	Card	for	Crohn’s	Disease	Activity	Index	 Date	of	Next	Clinic	Visit:	Patient	Name:		Clinic	Number:		 Seven	days	preceding	next	visit	(month	and	day)	Year:	 	 	 	 	 	 	 	 	1.	Number	of	liquid	or	soft	stools	 	 	 	 	 	 	 	 	2.	Abdominal	pain	(0	=	none,	1	=	mild,	2	=	moderate,	3	=	severe)	
	 	 	 	 	 	 	 	
3.	General	well	being	(0	=	generally	well,	1	=	slightly	under	par,	2	=	poor,	3	=	very	poor,	4	=	terrible)	
	 	 	 	 	 	 	 	
Instructions:	Complete	this	card	each	day	before	going	to	bed.	Your	answer	should	describe	the	preceding	24	hours.	Record	scores	in	proper	column	for	date	 	
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APPENDIX C 
Crohn’s Disease Activity Index. (Adapted from Best, 1976).111	
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